Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate ...
GlobalData on MSN

Second Pfizer Braftovi regimen shows benefit in mCRC

This recent readout follows successful data from another combination including Braftovi in mCRC.
Pharmabiz

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...
Healthline

Non-small Cell Lung Cancer

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
ascopubs.org

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study Supported by the NIH/NCI ...
Nasdaq

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with ...